This increase was found in the Chinese American study participants with Type II diabetes who had cataracts or
macular edema resulting in visual impairments.
Not exact matches
Regeneron Pharmaceuticals this week reported positive
results from two phase 3 trials of Eylea (aflibercept) injection for diabetic
macular edema (DME).
«These
results indicate a treatment breakthrough for saving the vision of people with diabetic
macular edema,» said Neil M. Bressler, M.D., chair of the DRCR.net and chief of the Retina Division at the Wilmer Eye Institute, Johns Hopkins University.
Long - term complications, especially if diabetes isn't properly treated, can
result, including cardiovascular disease, heart attack, eye disease, vision loss,
macular edema, kidney disease, and neuropathy.